Observational studyClinical rheumatology2026
Real-world effectiveness and safety of apremilast in psoriatic arthritis: results from the multicenter Italian MAPSI II study.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comments on "Real-world effectiveness and safety of apremilast in psoriatic arthritis: results from the multicenter Italian MAPSI II study".Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the effectiveness and safety of apremilast in the treatment of psoriatic arthritis (PsA) in a real-world setting across multiple rheumatology centers in Italy.
methodsMAPSI II is a multicenter, observational real-world study including adult patients with active PsA treated with apremilast. Patients were prospectively evaluated at baseline and after 6 and 12 months to assess effectiveness and safety. Clinical assessments included joint, skin, and patient-reported outcomes, namely Disease Activity Index for psoriatic arthritis based on 28 joint counts and C-reactive protein (DAPSA28-CRP), Leeds Enthesitis Index (LEI), dactylitis count, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Visual Analogue Scale (VAS) for pain and patient global assessment (PGA), Psoriatic Arthritis Impact of Disease questionnaire (PsAID-9), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and C-reactive protein (CRP). Safety was evaluated by recording adverse events (AEs) and serious adverse events (SAEs).
resultsOf the 139 enrolled patients, 100 completed the 6-month follow-up and 83 completed the 12-month visit. A significant reduction in PGA-VAS was observed from baseline (60.8 ± 20.5) to 12 months (30.3 ± 23.7; p < 0.001). LEI and CRP levels also improved significantly, while PASI and NAPSI remained unchanged. Apremilast was generally well tolerated; 38 AEs in 38 patients were recorded, mostly gastrointestinal. Two serious AEs were reported. Treatment discontinuation due to AEs occurred in 23 cases (60.5% of AE group).
conclusionApremilast demonstrated real-world clinical benefit in reducing disease activity and enthesitis in PsA patients, especially those with moderate disease and limited treatment options. Its safety profile and tolerability support its use in selected patients, potentially even before failure of other DMARDs. Key Points • This multicenter Italian real-world study evaluated the effectiveness of apremilast in patients with psoriatic arthritis. • Treatment with apremilast was associated with improvements in disease activity measures and a favorable safety profile in routine clinical practice. • The MAPSI II study provides additional real-world evidence on the use of apremilast in a heterogeneous psoriatic arthritis population.
Indexed as
Identifiers
42247059What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.